PAR 0.00% 21.0¢ paradigm biopharmaceuticals limited..

Chart, page-1882

  1. 60 Posts.
    lightbulb Created with Sketch. 10
    Short term price action isn't looking good. Support line broken and looks to be trending down sub $2 pending positive news from the FDA. If there is more than just a 'covid delay' and the FDA wants more information on the non clinical data or even restructure of trials I can see this going sub $1.50. Good buying op as eventually the phase 3 trial will begin (even if delayed) and we should see it back to $3.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.